Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 4, 2012, Pages 417-424

  Endsley, Aaron N ^a   Ho, Rodney J Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CD4; HIV; nanoparticles; targeted drug delivery

Indexed keywords

BINDING PROTEIN; INDINAVIR; MACROGOL 2000; SOLID LIPID NANOPARTICLE;

ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; LYMPH NODE; LYMPHOID TISSUE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; HIV-2; HUMANS; INDINAVIR; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES;

EID: 84870300931     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182653c1f     Document Type: Article

References (22)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860. (Pubitemid 28135961)
2. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-1295. (Pubitemid 27495741)
3. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A. 1997;94:12574-12579. (Pubitemid 27492570)
4. Ruiz L, van Lunzen J, Arno A, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS. 1999;13: F1-F8. (Pubitemid 29078057)
5. Brodie SJ, Patterson BK, Lewinsohn DA, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest. 2000;105:1407-1417. (Pubitemid 30322406)
6. Kinman L, Brodie SJ, Tsai CC, et al. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr. 2003;34:387-397. (Pubitemid 37444466)
7. Solas C, Lafeuillade A, Halfon P. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:238-243. (Pubitemid 36070370)
8. Kinman L, Bui T, Larsen K, et al. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr. 2006;42:155-161. (Pubitemid 43884709)
9. Tedla N, Dwyer J, Truskett P, et al. Phenotypic and functional characterization of lymphocytes derived from normal and HIV-1-infected human lymph nodes. Clin Exp Immunol. 1999;117:92-99. (Pubitemid 29292783)
10. Pollock S, Dwek RA, Burton DR, et al. N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS. 2008;22:1961-1969.
11. Duzgunes N, Pretzer E, Simoes S, et al. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mol Membr Biol. 1999;16:111-118. (Pubitemid 29179345)
12. Slepushkin VA, Salem II, Andreev SM, et al. Targeting of liposomes to HIV-1-infected cells by peptides derived from the CD4 receptor. Biochem Biophys Res Commun. 1996;227:827-833. (Pubitemid 26387811)
13. Clayton R, Ohagen A, Nicol F, et al. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antiviral Res. 2009;84:142-149.
14. Gagne JF, Desormeaux A, Perron S, et al. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta. 2002;1558:198-210. (Pubitemid 34081181)
15. Desormeaux A, Bergeron MG. Lymphoid tissue targeting of anti-HIV drugs using liposomes. Methods Enzymol. 2005;391:330-351. (Pubitemid 40254044)
16. Kaur A, Jain S, Tiwary AK. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 2008;58:61-74. (Pubitemid 351419158)
17. Jain SK, Gupta Y, Jain A, et al. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanome-dicine. 2008;4:41-48. (Pubitemid 351324205)
18. Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivu-dine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta. 2007;1770:681-686. (Pubitemid 46281473)
19. McCallus DE, Ugen KE, Sato AI, et al. Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule. Viral Immunol. 1992;5:163-172.
20. Paintsil E, Grill SP, Dutschman GE, et al. Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse tran-scriptase inhibitors after removal from culture. AIDS Res Ther. 2009;6:5.
21. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22:315-329.
22. Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther. 2009;9:111-119.